Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

At a White House event on Nov. 6 announcing price cuts for those blockbuster weight-loss drugs, Medicare and Medicaid Administrator Mehmet Oz made an astonishing claim.

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Denmark's GDP grew by the most in four years as Novo Nordisk continues to boost the small Nordic country's economy.

The report highlights Novo’s focus on three core pillars: operating with integrity, valuing our people and communities, and ...

The company announced that through the end of March, patients with prescriptions can buy the two lowest doses of Ozempic and ...

Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel.

​Novo Nordisk A/S (NYSE: NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo ...

Major stock indexes ended sharply lower to begin the week, which will see AI darling Nvidia and retail giants report ...

Novo Nordisk moved to cut U.S. prices on its leading GLP-1 weight-loss and diabetes drugs as competitive pressure from Eli ...

For a limited time, patients with a prescription can get a steep discount on the popular medications, as long as they’re ...